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ESM Table 1
ESM Table 1 Demographic data of human subjects tested in the study 
Sample Type Source Number Age at sampling 
years
median (IQR)
Follow-up duration
years
median (IQR)
new onset T1D OSR 80 13.9 (7.9–14.9)
Blood donors OSR 123 22.1 (16.7–26.1)
non-diabetic schoolchildren BOX 186 11.0 (10.2-11.7)
First degree relatives BOX 53 21.0 (13.0-35.9) 21.8 (15.6-24.4)
First degree relatives BDR 136 11.6 (5.29-18.1)
new onset T1D IASP 50 n.a.
Blood donors IASP 90 n.a.
IQR: Inter Quartile Range
OSR: San Raffele Scientific Institute
BOX: Bart's Oxford Famili Study
BDR: Belgian Diabetes Registry 
n.a. = not available
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ESM Fig. 1a
ESM Fig. 1a Effect of luciferase reporter placement on immunoprecipitation 
of (pro)insulin-luciferase antigens. The indicated serial dilutions of the anti-
human insulin HUI-018 mAb in an IAA negative normal human serum were 
tested in LIPS using the indicated constructs as antigens. Tests were 
performed in parallel without (black bars) or with (dotted bars) competition 
with 4.5x10-5 moles/L of unlabeled ACTRAPID insulin. Also shown are results 
from an IAA positive serum, the IAA negative diluent human serum, protein 
A+G sepharose alone, and the anti C-peptide mAb C-PEP01 directed against 
an epitope in the middle region of the C-peptide
NLuc-A chain proinsulin NLuc-A chain insulin
Proinsulin-NLuc Insulin-NLuc
ESM Fig. 1b
ESM Fig. 1b Effect of luciferase reporter placement on immunoprecipitation 
of (pro)insulin-luciferase antigens. The indicated serial dilutions of the anti-
human insulin HUI-018 mAb in an IAA negative normal human serum were 
tested in LIPS using the indicated constructs as antigens. Tests were 
performed in parallel without (black bars) or with (dotted bars) competition 
with 4.5x10-5 moles/L of unlabeled ACTRAPID insulin. Also shown are results 
from an IAA positive serum, the IAA negative diluent human serum, protein 
A+G sepharose alone, and the anti C-peptide mAb C-PEP01 directed against 
an epitope in the middle region of the C-peptide
ESM Fig. 2
ESM Fig. 2 Prolonged storage of luciferase tagged antigens has minimal 
impact on immunoprecipitation and luciferase activity. Single use aliquots 
of B chain-Nluc proinsulin were thawed after 2, 6, 10 months of storage at -
80°C and immunoprecipitated with the indicated serial dilutions of the anti-
human insulin mAb HUI018. The delta of light units between replicates with 
and without competition with 4.5x10-5 mol/L of unlabeled ACTRAPID insulin 
is shown
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ESM Fig. 3a
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ESM Fig. 3a Scatter plot of and ROC curve graphs of LIPS assays using 
alternative (pro)insulin-luciferase antigens. Human sera were used to 
immunoprecipitate the respective construct schematically depicted close to 
each graph. Tests were performed in parallel with or without competition 
with excess cold insulin and the delta of binding was used to calculate 
arbitrary units using serial dilutions of the HUI-018 mAb as a standard curve. 
Negative values were converted to 0.001 to plot on a log 2 scale. Results for 
the Insulin Nluc-A chain construct are incomplete. The dotted line in ROC 
graphs is the identity line
ESM Fig. 3b Scatter plot of and ROC curve graphs of LIPS assays using 
alternative (pro)insulin-luciferase antigens. Human sera were used to 
immunoprecipitate the respective construct schematically depicted close to 
each graph. Tests were performed in parallel with or without competition 
with excess cold insulin and the delta of binding was used to calculate 
arbitrary units using serial dilutions of the HUI-018 mAb as a standard curve. 
Negative values were converted to 0.001 to plot on a log 2 scale. Results for 
the Insulin Nluc-A chain construct are incomplete. The dotted line in ROC 
graphs is the identity line
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ESM Fig. 4
ESM Fig. 4 ROC curve analysis of high vs low risk relatives in RBA and in
LIPS. Comparison of the classical IAA RBA assay (blue line) and the B chain-
NLuc proinsulin LIPS (magenta line) in discriminating high risk (n=15) from
low risk (n=38) first degree relatives of T1D patients from the BOX study. On
the graph are shown the values of both the total ROC AUC and the partial
AUC, corresponding to an assay specificity greater than 90% (grey rectangle),
and the respective p values for the comparison between LIPS and RBA
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ESM Fig. 5
ESM Fig. 5 Correlation analysis of the B chain-NLuc proinsulin LIPS results in
IASP2015 between the Bristol and Milan laboratories. Results from both
T1D (left panels) and control (right panels) samples are shown. All results are
expressed either in light units (LU, top row) or arbitrary units (AU, bottom
row). LU values correspond to the delta of binding after competition, values
that became negative were omitted from the graphs
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ESM Fig. 6 ROC curve analysis of the B chain-NLuc proinsulin LIPS in
IASP2015. Results are shown for two different protocols adopting a long (48
hours, left graph) or a short (18 hours, right graph) incubation
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ESM Fig. 6
ESM Fig. 7 Optimized IAA LIPS results are highly correlated with RBA and
between B chain-NLuc proinsulin or insulin antigens in T1D samples. IAA
arbitrary units (AU) measured in the B chain-Nluc proinsulin or insulin LIPS
were compared in new onset T1D samples (n=80) (panel a). B chain-Nluc
proinsulin (panel b) or and B chain-Nluc insulin (panel c) LIPS results were
then compared RBA in the same samples. The Spearman r values from a
correlation analysis are shown in each graph
ESM Fig. 7
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ESM Fig. 8: Diabetes-free survival in FDRs stratified according to IAA status
and the number of other T1D autoantibodies. Shown are Kaplan-Meier
curves based on the measurement of IAA in FDRs from the Belgian Diabetes
Registry using LIPS (panels a-c-e-g) or RBA (panel b-d-f-h). Subjects in each
graph are classified according to the presence of other antibodies (0 to 3
additional autoAbs). For IAA positives (black lines) and IAA negatives (grey
lines) are shown the number of progressors, the total number of subjects in
each group, and the P value of the Mantel-Haenszel Log-Rank test
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